TNFRSF10D: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TNFRSF10D. The page also collects GeneMedi's different modalities and formats products for TNFRSF10D in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TNFRSF10D target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. [provided by RefSeq, Jul 2008]
Target ID | GM-MP1855 |
Target Name | TNFRSF10D |
Gene ID | 8793,716901 |
Gene Symbol and Synonyms | CD264,DCR2,TNFRSF10D,TRAIL-R4,TRAILR4,TRUNDD |
Uniprot Accession | Q9UBN6 |
Uniprot Entry Name | TR10D_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | Cancer |
Gene Ensembl | ENSG00000173530 |
Target Classification | Tumor-associated antigen (TAA) |
Pre-made anti-TNFRSF10D inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TNFRSF10D benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TNFRSF10D mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-TNFRSF10D monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Multi-species TR10D/ TNFRSF10D/ CD264 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TNFRSF10D VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
TNFRSF10D VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Pre-made TNFRSF10D viral vector in GM Promise-ORFTM
Cat No. | Products name | NM ID | Species | Type | Detail |
pGMLP003625 | human TNFRSF10D Lentivirus plasmid | NM_003840 | Human | Lentivirus plasmid | Detail |
vGMLP003625 | human TNFRSF10D Lentivirus particle | NM_003840 | Human | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.